Bio-Rad Laboratories, Inc.
BIO.B Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.8%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
Follow BIO.B
Alert me
Bio-Rad Laboratories, Inc. (BIO.B) EV/Sales
As of 27 October 2026, Bio-Rad Laboratories, Inc. (BIO.B) trades at a EV/Sales of 3.7×. Over the past ten years it has ranged from 1.4× (January 2015) to 8.1× (September 2021); the current reading is higher than 61% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.1× | (7.37%) |
| FY2024 | 3.4× | 1.41% |
| FY2023 | 3.4× | (18.01%) |
| FY2022 | 4.1× | (42.29%) |
| FY2021 | 7.1× | 11.93% |
| FY2020 | 6.3× | 41.34% |
| FY2019 | 4.5× | 58.88% |
| FY2018 | 2.8× | (9.68%) |
| FY2017 | 3.1× | 29.51% |
| FY2016 | 2.4× | 32.85% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 3.6× | 23.81% |
| Jun 2026 | 2.9× | 5.28% |
| Mar 2026 | 2.8× | (12.44%) |
| Dec 2025 | 3.1× | 8.03% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | 1.6× |
| BRKR Bruker Corporation compare | 3.0× |
| PODD Insulet Corporation compare | 3.5× |
| GMED Globus Medical, Inc. compare | 3.5× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.7× |
| BIO.B Bio-Rad Laboratories, Inc. | 3.8× |
| PEN Penumbra, Inc. compare | 7.7× |
| TXG 10x Genomics compare | 11.5× |
| GKOS Glaukos Corporation compare | 18.8× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on BIO.B
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement